Adjuvant Global Health Technology Fund, L.P.'s Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Oct 3, 2023
- Accession no.
- 0000950170-23-051728
- Filed
- Oct 3, 2023, 7:13 PM ET
- Trade date
- Sep 29-Oct 2, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.70M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Adjuvant Global Health Technology Fund, L.P.CIK 0001783165 | 10% Owner |
| Adjuvant Global Health Technology Fund DE, L.P.CIK 0001799812 | 10% Owner |
| Adjuvant Capital Management, LLCCIK 0001935084 | 10% Owner |
| Adjuvant Capital GP, L.P.CIK 0001935100 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 29, 2023 | Common Stock | SSaleDisposed | −83,337 | $16.28 | −$1,356,726.36 | 2,086,343 | Direct | |
| Sep 29, 2023 | Common Stock | SSaleDisposed | −15,764 | $16.28 | −$256,637.92 | 394,639 | Indirect | |
| Oct 2, 2023 | Common Stock | SSaleDisposed | −4,770 | $16.07 | −$76,653.9 | 2,081,573 | Direct | |
| Oct 2, 2023 | Common Stock | SSaleDisposed | −902 | $16.07 | −$14,495.14 | 393,737 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.